CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, today announced Dr. Damon Broyles, MD, the VP of Clinical Innovation at Mercy Technology Services (MTS), the technical support arm of Mercy Healthcare, has joined Cardio Diagnostics as a strategic advisor.
Strategic advisors at Cardio Diagnostics are pivotal in providing guidance and counsel to the management team. Dr. Broyles will leverage his extensive experience and knowledge in the healthcare industry to collaborate closely with the team to navigate complex challenges and capitalize on emerging opportunities in the dynamic cardiovascular disease, precision medicine, and innovation landscapes.
In his current role as the VP of Clinical Innovation at MTS, Dr. Broyles leads the charge on clinical innovation initiatives. He also serves as the Medical Director for the Multi-Cancer Early Detection program, emphasizing his dedication to cutting-edge solutions in healthcare. Dr. Broyles is a key figure in the development of Mercy's Department of Precision Medicine. He serves as an informatics facilitator and innovator for both MTS and Mercy, where he is responsible for driving value-based population health initiatives, including one of the nation's largest Accountable Care Organizations (ACOs). His exceptional leadership and strategic vision have played an integral role in the growth and success of the organization.
"I am thrilled to join Cardio Diagnostics and contribute my expertise in healthcare innovation and precision medicine," says Dr. Damon Broyles, VP of Clinical Innovation at Mercy Technology Services. "As a strategic advisor, I am eager to collaborate with the team to drive innovation in the cardiovascular disease landscape. With the power of artificial intelligence and precision medicine, I believe that Cardio Diagnostics is poised to transform the field of cardiovascular medicine and improve patient outcomes on a global scale. I look forward to playing a role in advancing this mission and making a meaningful impact in the lives of patients and clinicians."
Dr. Broyles has developed a broad and expansive lens of the healthcare industry through a wide array of board appointments and advisory services for large technology firms, dynamic startups, and VC and institutional research teams. His experience and knowledge have helped cultivate innovation initiatives and development throughout the Midwest region in the areas of healthcare technology, clinical informatics, biotechnology, and entrepreneurship in medicine. He utilizes this unique expertise to enhance and optimize enterprise clinical systems for the 4,200 integrated providers, 44 hospitals, and 925 outpatient and clinic facilities encompassing the Mercy health system.
"Dr. Broyles is a highly respected clinical and thought leader in the healthcare industry, and we are thrilled to have him join Cardio Diagnostics as a strategic advisor," said Meesha Dogan, Ph.D., CEO of Cardio Diagnostics Holdings, Inc. "His extensive expertise and operational proficiency at the intersection of innovation, precision medicine, and emerging technologies make him the perfect addition to our team. We are confident that his insights and guidance will help us identify new growth opportunities, mitigate risks, and create long-term value for our company, customers, and stakeholders. With Dr. Broyles on board, we are excited to advance our mission of bringing artificial intelligence-powered precision cardiovascular medicine to patients worldwide."
About Cardio Diagnostics
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for enabling improved prevention, early detection, and assists in the treatment of cardiovascular disease. For more information, please visit www.cardiodiagnosticsinc.com.
This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "should," "believe," and similar expressions are intended to identify such forward-looking statements. Forward-looking statements include, without limitation, the Company’s expectations with respect to future performance, development and commercialization of products and services, the potential benefits and impact of the Company’s products and services, potential regulatory approvals, and the size and potential growth of current or future markets for the Company’s products and services. Forward-looking statements are statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties that could cause the actual results to differ materially from the expected results. These statements are based on various assumptions, whether or not identified in this press release, and are not intended to serve as, and they must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Factors that may cause such differences include, but are not limited to: the success, cost and timing of the Company’s product development and commercialization activities, including the degree that Epi+Gen CHD™ and PrecisionCHD™ tests are accepted and adopted by patients, healthcare professionals and participants in other key channels; the impact of COVID-19 on the Company’s business; economic conditions, dependence on management, dilution to stockholders, lack of capital, changes in laws or regulations, the effects of rapid growth upon the Company and the ability of management to execute our growth strategy and ability to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company’s ability to compete, regulatory matters, protection of technology, lack of industry standards, the effects of competition and the ability of the Company to obtain future financing. Such factors could materially adversely affect the Company’s financial performance and could cause the Company’s actual results for future periods to differ materially from any opinions or statements expressed within this press release.